Inhibrx Biosciences GAAP EPS of -$2.28
Source: SeekingAlpha
2025-11-14 06:34:06 ET
More on Inhibrx Biosciences
- Inhibrx Biosciences: Cruising Toward FDA Approval, But Getting Ahead Of Itself
- Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing
- Inhibrx surges on meeting key goal in trial for ozekibart for rare bone cancer
- Seeking Alpha’s Quant Rating on Inhibrx Biosciences
- Historical earnings data for Inhibrx Biosciences
Read the full article on Seeking Alpha
For further details see:
Inhibrx Biosciences GAAP EPS of -$2.28
Inhibrx Biosciences Inc.
NASDAQ: INBX
INBX Trading
-2.78% G/L:
$68.33 Last:
90,695 Volume:
$70.50 Open:
INBX Latest News
INBX Stock Data
$1,212,947,749
8,822,231
0.71%
112
N/A
Biotechnology & Life Sciences
Healthcare
US
La Jolla
